Inimex Corp provide services to get you the best Asian Manufacturers direct dealing with you. Inimex, Inimexcorp, Chinese manufacturers, Chinese Suppliers, Asian Trade, Trade, Asia manufacturers, Taiwan, Thailand Manufacuters, Import Asia, Importer, Wholesale Chinese Products, Umbrella, Chinese Products, Asia direct, Asia import, Asia export.
VYREX CORPORATION, based in La Jolla, California, is a biopharmaceutical discovery and development company. Vyrex is engaged in research, discovery and development of innovative small molecule pharmaceutical, nutraceutical and cosmeceutical products for treatment and prevention of various diseases and disorders associated with human aging. Sheldon S. Hendler, Ph.D., M.D., the Company's Chairman, Founder, and Director of Scientific and Medical Affairs, has broad experience in multiple scientific and medical disciplines, including biochemistry, molecular biology, genetics, virology, medicinal chemistry, basic research, clinical research, internal medicine and dermatology. He is published in the world's leading scientific and medical journals, including The New England Journal of Medicine, Nature and Proceedings of the National Academy of Sciences and is a named inventor on numerous patents, including those relating to the Company's technologies. Dr. Hendler has also written several award-winning popular books, including The Doctors' Vitamin and Mineral Encyclopedia (Simon & Schuster) and the Physicians' Desk Reference (PDR) for Nutritional Supplements. The PDR® for Nutritional Supplements comprehensively evaluates all of the various nutritional supplements used throughout the world. It is "considered the standard reference book in the field" (New York Times, March 9,2004). Dr. Hendler is a Clinical Professor of Medicine (Voluntary), University of California, San Diego and an Attending Physician at Scripps Mercy Hospital in San Diego. He received his Ph.D. in biochemistry from Columbia University and his M.D. from the University of California, San Diego and is a Fellow of the American Institute of Chemists and the American College of Nutrition. Dr. Hendler is also Co-Editor-in-Chief of the international, peer-reviewed Journal of Medicinal Food (Mary Ann Liebert, Publishers). G. Dale Garlow became Vyrex's Chief Executive Officer and President in 2000. He succeeded Dr. Sheldon Hendler, becoming the second CEO and President in Vyrex's history. In 2000, he was also appointed a member of the Vyrex Board of Directors. Mr. Garlow has extensive and diversified managerial skills in the pharmaceutical, biotech and nutraceutical industries. Mr. Garlow's prior key executive positions include: Partner in Integra LLC, a Company involved in operations, sales and marketing of pharmaceuticals, over-the-counter products, vitamins and medical diagnostics; President, CEO and Co-Founder of FHC Corporation, a Company that developed and obtained exclusive world wide marketing rights for a home pregnancy test which was sold in an exclusive supply agreement to Warner Lambert for marketing as their brand ept®; President and CEO of Whiteworth/Towne Paulsen a manufacturer and distributor of health and beauty aids and generic prescription pharmaceuticals, and Regional Director of Administration and Distribution for the Upjohn Pharmaceutical Company. Garlow has served on the boards of a number of companies, including DNA Technologies and Nucleic Assays. He majored in business administration and marketing at the University of Missouri. Michael L. Eagle recently retired as the Vice President of Manufacturing for Eli Lilly and Company. He was with Eli Lilly for 18 years beginning as the Vice President of Manufacturing for Advanced Cardiovascular Systems, now a part of Guidant Corporation. Mr. Eagle currently sits on the Boards of several medical device and equipment manufacturers and is a founding member of Barnard Life Sciences, LLC, a firm focusing on life science businesses. Mr. Eagle's prior key executive positions include; Senior Vice President of Operations for Advanced Cardiovascular Systems, President and CEO of IVAC Corporation (another Eli Lilly subsidiary) and Vice President of the Medical Device and Diagnostics Division of Eli Lilly with responsibility for all vascular, surgical and medical device businesses, including those businesses located in Japan. Michael L. Eagle is a member of the Board of Directors. Richard McKee, Jr. is Managing General Partner of Dynamic Value Partners, Ltd., a Florida investment partnership specializing in small-cap stocks. Previously he served as a director and portfolio manager at Fundamental Management Corporation in Miami, Florida and as Vice President of First Equity Corporation of Florida, a regional investment-banking firm. Mr. Mckee is a graduate of Brown University. Richard McKee, Jr. is a member of the Board of Directors. Tom K. Larson, Jr. is President and CEO of Accelerated Capital Funding, a start up company involved in raising capital for housing for Native Americans, Handicapped and Elderly Individuals. Prior to joining Vyrex, Mr Larson served as Vice President, Finance and Administration and CFO of INAMED Corporation, a global surgical and medical device company. Mr. Larson's previous positions include Vice President, Finance and CFO of a privately held specialty bed manufacturer, Vice President, Finance and CFO Revell Corporation, and held a number of key executive financial and administrative positions at Xerox Corporation. In addition he was an Equity Owner and Operation Officer of four separate corporations and is experienced in turnaround situations. Tom K. Larson, Jr. is a member of the Board of Directors. Vyrex Corporation is a La Jolla, California based Biopharmaceutical Company seeking to discover and develop pharmaceutical, nutraceutical and cosmeceutical products for the treatment and prevention of respiratory, cardiovascular and neurodegenerative diseases and conditions associated with aging. To date the Company has focused on developing targeted anti-oxidant therapeutics for respiratory, neurological and cardiovascular diseases and the development of nutraceuticals and cosmeceuticals for the support of certain age related conditions.
Formed in 1997, Phage Therapeutics, Inc. (PhageTx) is a United States corporation dedicated to the discovery, development and regulatory approval of bacteriophage products for the treatment of antibiotic-resistant and other bacterial infectious diseases. PhageTx is already proving itself to be a leader in this field. PhageTx has made significant progress with its top product candidate - a bacteriophage biopharmaceutical agent being developed to treat antibiotic-resistant strains of Staphylococcus aureus (Staph) and other Staph species, the primary bacteria that cause hospital-acquired Staph infections. The emerging product has successfully completed a manufacturing development program, and formal pre-clinical testing has begun. PhageTx is also currently developing bacteriophage products for two other antibiotic-resistant infectious agents, namely, Mycobacterium tuberculosis (Tuberculosis or TB, and the multi-drug-resistant forms of TB known as MDRTB) and Pseudomonas aeruginosa. back to top
MRPath was cofounded by Drs. Robert Lontz and G. Allan Johnson. The MRPath president, Dr. Lontz previously served as Chief Executive Officer of Magnetic Imaging Technologies Incorporated. Dr. G. Allan Johnson is the Professor of Radiology and Physics and Director of the Center for In Vivo Microscopy at the Duke University Medical Center. Much of the technology of MRPath is inspired by magnetic resonance (MR) techniques developed under National Institutes of Health research awards. These include a grant from the National Cancer Institute to develop a reference of high resolution mouse MRI (The Visible Mouse); and applications of MR imaging for rodent teratology, neurotoxicology, and In Vivo studies for the National Institute of Environmental Health Sciences. The MRPath founders were initially motivated by a desire to make available a heretofore expensive and specialized imaging capability to a broad community of users in research and industry. In addition to special expertise in MR microscopy, the company offers other imaging modalities, the management of image intense databases, and their integration within protocols and studies. This experience led to the creation of a software product line, which addresses many of the problems in scientific image management. MRPath is the second biotechnology startup for Drs.
Cell NetwoRx LLC is focused on the discovery and development of small molecule drugs that act on our proprietary angiogenesis target with therapeutic applications in eye disease, oncology and wound healing. The drug discovery process is driven by Cell NetwoRx's proprietary cell based assay technology, the Pathway Assay Matrix (PAMÔ). By integrating disease pathway target identification with PAMÔ we enable small molecule lead development in the context of the patient disease state.
UCB Research, Inc., located in Cambridge, Massachusetts, is a cutting edge research and discovery company which supports UCB Pharma's drug development pipeline with therapeutic candidates for allergic and central nervous system disorders. Our research utilizes state-of-the-art tools for target discovery, chemistry and pharmacology. Though we are rapidly growing, we intentionally remain small enough to maintain our entrepreneurial environment that encourages personal initiative. Therefore, we have created a dynamic and innovative working environment with a broad range of drug discovery capabilities. UCB Research is a subsidiary of UCB Pharma, a global research-based pharmaceutical company with 4,500 employees based in Brussels, Belgium and U.S. headquarters in Atlanta, Georgia. The company is a global leader in the research, manufacture, and marketing of innovative therapeutics for allergy and central nervous system disorders. UCB Pharma's products include Zyrtec, (ceterizine HCl), globally the leading antihistamine, and Keppra, (levetiracetam), a novel anti-epileptic drug approved in the U.S. and Europe in 2000. UCB Pharma is part of the UCB Group, which in addition to pharmaceuticals, includes both chemicals and films sectors. UCB Group currently employs over 8,500 people worldwide. The company's three sectors seek to promote health, well being and an improved quality of life.
Sterix Limited is a private biopharmaceutical company formed in 1998 to advance research from two leading academic research groups: a steroid biology research group at St Mary's Hospital, London (Imperial College School Of Medicine) led by Professor Mike Reed and a medicinal chemistry group at the University of Bath led by Professor Barry Potter. Sterix has it's head quartered at the Oxford Science Park and continues to undertake research both at Bath and St Mary's. The current focus of the group is the design and discovery of novel steroid derivatives and small molecule drugs that modulate steroid metabolism. Other areas of interest include the design of combined aromatase-sulphatase inhibitors, small molecule angiogenesis inhibitors and a novel drug delivery system.
http://www.ismtherapeutics.com
ISM Therapeutics is developing a radioprotective drug based on our ISM technology under a government contract for the DOD. ISM Therapeutics has discovered and developed an ISM-based therapeutic for cystic fibrosis: INO-4995 was discovered and developed to treat cystic fibrosis and human clinical trials are targeted to begin in 2007. The cost of developing the CF drug through phase I trials is approximately $12M and will take approximately 2 years. In addition, ISM Therapeutics has several compounds in its portfolio with anti-inflammatory activity. Key AssetsActive compound collection: ISM Therapeutics has identified, synthesized and tested distinct, patented active compound series that have yielded a number of drug candidates with potential therapeutic applications. Scientific expertise.Our founder and Chief Scientific Officer, Dr. Alexis Traynor-Kaplan, has over 25 years expertise in the area and identified one of the first ISMs. ISM Therapeutics has a world-renowned SAB with expertise in ISM technologies and chemistry. Control of critical patents. ISM Therapeutics co-owns and has an exclusive worldwide license from the University of California, San Diego for 3 issued patents covering key composition of matter and method of use claims. ISM Therapeutics also maintains an extensive portfolio of domestic and international filings on inventions derived from internal research. Company Funding to date:Approximately $5M in non-dilutive investments: 2000-2006: $1.9M in Cystic Fibrosis Foundation grants to discover and develop a CF drug, INO-4995 1998-2006: $2M in NIH SBIR grants to initiate pipeline programs in CF, cancer and inflammation 10/2006- 10/2007: $1.1M DOD non-dilutive government appropriation to develop ISMs as radioprotectants $2.5M in an investment series A round (2004) (primarily angels, founders and partners) For more information, please contact:
Chemizon is a rapidly growing drug discovery company with operations in the US, Korea and China. Chemizon's co-founder and CEO, Dr. Tony Piscopio was a co-founder of Array Biopharma, a leading biotech company located in Boulder, Colorado, USA and served as its VP of Chemistry for nine years. Chemizon's management team brings a high level of expertise to the IND generation process having successfully brought forward several candidates to clinical trials. Chemizon's core competency lies in drug discovery: we assist our partners in converting their target know-how into breakthrough medicines. Our team brings considerable experience to a wide range of therapeutic areas including oncology, inflammation, cardiovascular, CNS, anti infective and metabolic diseases. Our goal is to accelerate our collaborator's drug discovery efforts using a vertically integrated discovery platform that includes Progenitors, Leadz, ADMET and radiolabeling capabilities. Chemizon's technical team aims to develop quality, ,best-in-class' candidates that can better survive the rigors of the development process. Research collaborations are undertaken at two world class facilities: a 15,000 sq ft facility in the Seongnam Biotech hub, Seoul, Korea and a 36,000 sq ft facility located at the prestigious Tsinghua Science Park in Beijing, China. Both facilities are equipped with a superb IT infrastructure, kilo labs and state-of-the-art analytical suites (including 400 NMR, LC-MS and LC). Video conferencing capabilities and VPN's enable seamless communication and secure data transfer with our partners who have immediate access to time-critical information. Asia has grown significantly in terms of providing quality service in the past decade and western pharmaceuticals have taken notice. While advanced intermediates, process development, custom synthesis are now routinely outsourced to Asia, drug discovery partnering is still in its infancy. Drug discovery, unlike some other areas in the life sciences cycle, requires expertise in medicinal chemistry, biology and pharmacokinetics along with a clear understanding of the steps involved with filing a successful IND application. Chemizon, with its repatriated management and technical teams is ideally positioned to become the partner of choice for life science organizations seeking to cost effectively accelerate their drug discovery programs. To learn more about Chemizon, Inc., please choose a link below.
Neuro Bioscience is an emerging biotechnology company that is focused on the development and commercialization of innovative treatments to treat Central Nervous System diseases and disorders. The Company has products in development targeted against Alzheimer's Disease, Depression, Multiple Sclerosis, and Parkinson's Disease, and a product to treat a non CNS afflicition for the treatment of Arthritis. Neuro Bioscience is focused on developing products that will provide a much better quality of life to the patients that we hope our drugs will benefit at the same time as returning value to the shareholders that have shown faith in the company, its management and products. This website will guide you through the company, the people behind it and the products that it is developing. :: Neuro Bioscience Inc.
AT-GC BioPharm was founded in 2004 with a vision that still drives us today: to transcend the limits of biopharmaceutical manufacturingsm. We believe that by applying the methods of leading technologies to the art of miniaturization, automation and control systems, we will develop breakthrough technology platform that will fundamentally change the way biopharmaceuticals are manufactured. We at AT-GC BioPharm are following the principle that the quality of the product can be assured only by focusing the attention on the product rather than documentary requirements. Only product focused quality approach, when used with the regulatory agency required documentary approach will meet the stringent safety requirements of educated society and consumers. In its early years, AT-GC BioPharm focused on building top-notch science and business teams to help achieve this vision. Attracted by our scientific leadership, entrepreneurial spirit, and aggressive but judicious growth, AT-GC BioPharm quickly began to earn the attention and respect of many of the best scientists and business people from around the world. Beginning in 20044, AT-GC BioPharm created strategic alliances with pharmaceutical and biotechnology companies. These alliances provided AT-GC BioPharm with leading edge technologies that we used to develop and enhance our intelligent manufacturing platform and related products. With an innovative, integrated science and technology platform, expertise in drug-target manufacturing, the company is geared for Quality Assured ManufacturingTM. As AT-GC BioPharm is nearing its first anniversary, the company has revenue pipeline. Today, AT-GC BioPharm has two leading products, proven commercial capabilities, and many product candidates in varying stages of development. We are continually evolving to ensure that our research and development efforts stay current with the demand for new biosensor and manufacturing related products that will make a genuine difference in the way biopharmaceuticals are manufactured.
Endocrine Pharmaceuticals ('Endocrine') of North Hampshire, UK, is a life sciences company with expertise in the hormonal regulation of tissue mass and integrity. Additional areas of interest are fertility and lifespan. The company's discovery and research focus, micrin, is a naturally occurring mammalian hormonal inhibitor of tissue masses and an upholder of cellular integrity. Micrin prevents runaway tissue overgrowth and probably inhibits tumour formation and progression as well. Drug candidates related to micrin are under investigation for therapeutic benefit in a range of benign and malignant tissue overgrowth conditions affecting the pituitary, prostate, breast, heart, kidneys and other tissues, as well as in infertility. Endocrine optimises operational costs by conducting research through scientists in universities and research institutes in the UK and Australia. The company's chief executive is Dr John Hart, an endocrinologist by background with significant experience of drug development and exploitation. The company is privately held, by about 80 shareholders. Endocrine has a professionally constituted Board with technical, legal and commercial expertise, plus an internationally well-regarded Scientific Advisory Board, which includes notable leaders in the fields of endocrinology, physiology and biochemistry.
Created after a breakthrough discovery in protein research, TriMed Research, Inc. is a joint venture of the University of Nebraska Medical Center, UNeMed Corporation and Tridelta Development, Ltd. TriMed Research's mission is to research and commercially develop therapeutic products, primarily related to the company's patented discovery of the mammary gland protein designated as MAA. Because synthetic versions of the MAA protein are shown to be bioactive and able to initiate protective processes in the intestine, this discovery may significantly reduce bacterial and viral gastro-intestinal infections in humans and animals. The discovery of MAA offers a wide variety of potential applications including: Prevention of life-threatening diseases experienced by premature infants; Reduction of infectious diarrhea among herd animals and possibly bovine mastitis; Reduction of the debilitating side-effects of cancer treatments; and Prevention of "travelers' diarrhea."
SerOptix Inc is a research and development-based biotechnology company located in Woburn, Massachusetts. Biotechnology in the post-genomic era has seen the refocusing of informatics technology onto molecular discovery and molecular signature analysis of human disease. The pharmaceutical industry has already recognized the value of molecular target identification as evidenced by recent multi hundred million dollar deals in this sector. SerOptix has established proprietary technologies and systems for molecular target discovery through identification of unique disease signatures based on the intrinsic fluorescence properties of disease-related molecules. Although disease-specific fluorescent signatures can be partly or completely obscured by molecules common to all individuals, preclinical studies at SerOptix have demonstrated methods designed to fractionate and selectively measure "fluorophore" populations. Our platform technology "Spectra-Molecular Informatics" or 'SMI,' encompasses these advances through a combination of spectroscopy, biochemistry and informatics. The Company has successfully exploited this technology to demonstrate the applicability of the intrinsic fluorescence spectra-molecular signatures for diagnostics and for the identification of disease-specific molecular targets. SerOptix is building on this initial development to integrate its novel molecular profiling tools, the INFLIT systems with its comprehensive SMI platform. The combined technology will be focused on a broad set of proprietary and pharmaceutical industry-sponsored programs for molecular target identification for drug discovery and diagnostic development efforts. The Company is continuing to build its technology portfolio to further enhance the power of its Spectra-Molecular-Informatics Platform to efficiently extract high value knowledge from fluorescence-based molecular profiling, and support novel drug discovery and diagnostics development. The Company foresees near term revenue from partner sponsored studies, and the licensing of early stage SMI results. SerOptix is raising capital to rapidly build business opportunities based on this technology. Our business model, projects profitability within a short time frame, and sustainable growth in subsequent years from multiple R&D partnerships and the later stage outlicensing of proprietary programs. The Company plans to execute the following strategy: Integrate novel INFLIT instrumentation and INFLIT systems with the core SMI platform and establish intellectual property protection for this new technology. Exploit these technologies for revenue, obtained through marketing partnerships with instrument and systems providers to meet their critical client needs in functional genomics, labile product analysis and other biotechnology and product assurance applications. Utilize this foundation to engineer an enhanced and comprehensive SMI platform based on intrinsic fluorescence and complete the development and establishment of a proprietary normal database of Spectra-Molecular signatures and complement the Company's discovery paradigms with subscription-based revenue built on the value of its proprietary databases Direct the power of SMI and its database to the identification of disease candidates, including specific degenerative & metabolic diseases and cancers in order to define disease-specific molecular targets for licensing and co-development with corporate partners. Develop selected SMI applications to advance high value drug discovery and diagnostic projects funded by industry partners. Receive with enhanced revenues based on client validation and leverage successful partnerships to increase future project revenues. Expand the research and development capacity of the Company and to enhance SerOptix' ability to participate in government sponsored R&D initiatives by establishing academic partnerships through SerOptix-sponsored SMI research programs. Continue to aggressively build an intellectual property portfolio that protects the Company's innovations. The U.S. Patent and Trademark Office has already issued the company two patents and additional U.S. applications covering specific methodologies and applications of the SMI Platform are being pursued.
RiboGene, Inc. is a drug discovery company focused on the identification of novel leads and the development of potential drug candidates for the treatment of infectious diseases. The Company's drug discovery efforts target bacterial, fungal and viral infections for which the efficacy of existing therapies is being threatened by the emergence of drug resistance or for which existing therapies have had limited effectiveness. The Company's drug discovery technology is based on the translational control of gene expression. The Company is using its platform technology to discover compounds that inhibit or interfere with pathogen specific translation. To compliment its drug discovery efforts, the Company also seeks to in-license or acquire compounds with demonstrated activity relevant to certain therapeutic targets. Consistent with this strategy, the Company acquired Emitasol, an intranasal form of metoclopramide. (Source: 10-K405)
http://www.cellulargenomics.com
CGI Pharmaceuticals, Inc. is a private, development-stage pharmaceutical company that has leveraged its proprietary chemistry and kinase biology expertise to discover and develop an innovative pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. Founded out of Yale University in 2000, CGI's corporate headquarters and research laboratories are located in Branford, Connecticut.
EBI's primary target market is a group of disorders commonly known as the systemic inflammatory response syndrome ("SIRS"), including the clinical condition known as sepsis. Of the various inflammatory disorders, sepsis causes the greatest negative economic and medical consequences. It is the leading cause of death in hospital intensive care units worldwide, costing the US healthcare system an estimated $18 billion per year, and causing 1,400 deaths per day in the developed countries of the world. In SIRS/sepsis the body's immune system overreacts to an infection or other stress leading to severe organ damage and death. SIRS acts by triggering a series of chemical reactions in the body in a sequential, cascade,like process. In many cases, uncontrolled cascades result in death. The goal of the Company's therapeutic development initiative is to modulate the sequence of reactions in the immune cascade with patented small molecule sub-fractions of human hormones that attenuate an uncontrolled immune response. Our drug candidates have additional clinical applications involving similar inflammatory pathologies involved in radiation sickness, renal failure, avian flu and anthrax infections. EA-230 has completed Phase I single and multi-dose clinical trials including the Phase I expansion, LPS Proof of Concept, without material adverse reactions and the Company is currently preparing for Phase II clinical trials.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory